SYN023 (Zamerovimab and Mazorelvimab Injection)
Product Description
Sinovac Biotech Ltd.
-
Country/Region:China
-
On CPHI since:2018
-
Certificates:2
-
Employees:1000 - 4999
Company types
Primary activities
Categories
Specifications
Sinovac Biotech Ltd.
-
Country/Region:China
-
On CPHI since:2018
-
Certificates:2
-
Employees:1000 - 4999
Company types
Primary activities
More Products from Sinovac Biotech Ltd. (3)
-
Product Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
Launched in 2021.
Prequalified by the World Health Organization.
Manufacturing process is result of technology transfer from the WHO and Netherlands-based lntravacc.
Good safety with zero preservatives and antibiotics.
Read more on: http://ww... -
Product Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®
• Hepatitis A Vaccine (Human Diploid Cell), Inactivated – Healive® Launched in 2002
Hepatitis A & Hepatitis B Combined Vaccine – Bilive®
Launched in 2005
Healive® is:
Prequalified by the World Health Organization.
Provides susta... -
Product Influenza Vaccine (Split Virion), lnactivated – Anflu®
Influenza Vaccine (Split Virion), lnactivated – Anflu®
Pandemic Influenza Vaccine, lnactivated, Adjuvanted – Panflu®
H1N1 Influenza A Vaccine (Split Virion), lnactivated – Panflu.1®
Influenza Vaccine (Split Virion), lnactivated, Quadrivalent – TetrAnflu®
Anflu®, preservative-free ...
Sinovac Biotech Ltd. resources (2)
-
News SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.
-
Brochure SINOVAC Vaccines leaflets
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.


